Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma total assets
Total assets on the balance sheet at the end of each period.
Arbutus Biopharma's total assets was $339.70M at Sep 30, 2026. For fiscal 2025 it was $94.62M, down 28.2% from the year before. Over ten years it grew -18.3% a year on average. The highest annual figure on record is $712.29M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.62M | -28.2% |
| FY2024 | Dec 31, 2024 | $131.71M | -8.8% |
| FY2023 | Dec 31, 2023 | $144.40M | -26.1% |
| FY2022 | Dec 31, 2022 | $195.42M | -4.4% |
| FY2021 | Dec 31, 2021 | $204.49M | +49.2% |
| FY2020 | Dec 31, 2020 | $137.08M | +29.9% |
| FY2019 | Dec 31, 2019 | $105.54M | -53.7% |
| FY2018 | Dec 31, 2018 | $227.91M | -3.9% |
| FY2017 | Dec 31, 2017 | $237.16M | -14.0% |
| FY2016 | Dec 31, 2016 | $275.92M | -61.3% |
| FY2015 | Dec 31, 2015 | $712.29M | +502.7% |
| FY2014 | Dec 31, 2014 | $118.18M | +64.8% |
| FY2013 | Dec 31, 2013 | $71.72M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $339.70M | +247.7% |
| Q2 FY2026 | Jun 30, 2026 | $274.03M | +165.4% |
| Q1 FY2026 | Mar 31, 2026 | $277.16M | +136.9% |
| Q4 FY2025 | Dec 31, 2025 | $94.62M | -28.2% |
| Q3 FY2025 | Sep 30, 2025 | $97.71M | -30.4% |
| Q2 FY2025 | Jun 30, 2025 | $103.27M | -35.5% |
| Q1 FY2025 | Mar 31, 2025 | $117.01M | -22.1% |
| Q4 FY2024 | Dec 31, 2024 | $131.71M | -8.8% |
| Q3 FY2024 | Sep 30, 2024 | $140.44M | -11.5% |
| Q2 FY2024 | Jun 30, 2024 | $160.04M | -9.5% |
| Q1 FY2024 | Mar 31, 2024 | $150.29M | -21.4% |
| Q4 FY2023 | Dec 31, 2023 | $144.40M | -26.1% |
| Q3 FY2023 | Sep 30, 2023 | $158.64M | -22.2% |
| Q2 FY2023 | Jun 30, 2023 | $176.82M | -18.1% |
| Q1 FY2023 | Mar 31, 2023 | $191.22M | -19.3% |
| Q4 FY2022 | Dec 31, 2022 | $195.42M | -4.4% |
| Q3 FY2022 | Sep 30, 2022 | $203.80M | +23.1% |
| Q2 FY2022 | Jun 30, 2022 | $215.84M | +59.4% |
| Q1 FY2022 | Mar 31, 2022 | $236.88M | +62.0% |
| Q4 FY2021 | Dec 31, 2021 | $204.49M | +49.2% |
| Q3 FY2021 | Sep 30, 2021 | $165.60M | +26.3% |
| Q2 FY2021 | Jun 30, 2021 | $135.38M | +38.7% |
| Q1 FY2021 | Mar 31, 2021 | $146.24M | +42.5% |
| Q4 FY2020 | Dec 31, 2020 | $137.08M | +29.9% |
| Q3 FY2020 | Sep 30, 2020 | $131.10M | +11.8% |
| Q2 FY2020 | Jun 30, 2020 | $97.63M | -49.3% |
| Q1 FY2020 | Mar 31, 2020 | $102.61M | -51.0% |
| Q4 FY2019 | Dec 31, 2019 | $105.54M | -53.7% |
| Q3 FY2019 | Sep 30, 2019 | $117.28M | -52.2% |
| Q2 FY2019 | Jun 30, 2019 | $192.57M | -30.5% |
| Q1 FY2019 | Mar 31, 2019 | $209.22M | -22.5% |
| Q4 FY2018 | Dec 31, 2018 | $227.91M | -3.9% |
| Q3 FY2018 | Sep 30, 2018 | $245.42M | +2.3% |
| Q2 FY2018 | Jun 30, 2018 | $277.01M | +8.6% |
| Q1 FY2018 | Mar 31, 2018 | $270.03M | +0.7% |
| Q4 FY2017 | Dec 31, 2017 | $237.16M | -14.0% |
| Q3 FY2017 | Sep 30, 2017 | $239.85M | – |
| Q2 FY2017 | Jun 30, 2017 | $255.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $268.14M | – |
| Q4 FY2016 | Dec 31, 2016 | $275.92M | – |
See a number that looks wrong?